Rivoglitazone Explained

Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.^{[1] [2]}

It is being developed by Daiichi Sankyo.

Notes and References

1. Schimke K, Davis TM . Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes . Current Opinion in Investigational Drugs . 8 . 4 . 338–344 . April 2007 . 17458185 .
2. Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GT, Wong CK, Leung GT, Lee KF, Yeung CY, Chan JC . 6 . A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes . Diabetes, Obesity & Metabolism . 13 . 9 . 806–813 . September 2011 . 21492364 . 10.1111/j.1463-1326.2011.01411.x . 24974160 .